TKIS

Aumolertinib, a newer drug that targets the epidermal growth factor receptor (EGFR), has been tested in two hospitals on patients with a rare form of lung cancer. The cancer cells carry uncommon deletions in exon 19 of the EGFR gene, a pattern that often makes standard treatments less reliable. R

People with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) often rely on covalent Bruton's Tyrosine Kinase inhibitors (cBTKis) to manage their condition. These drugs are crucial, but they come with a catch: they can sometimes lead to heart problems. Doctors have been digging i